CICC Raises WUXI BIO Target Price to HK$48, Keeps Outperform Rating

Stock News03-26

CICC has issued a research report stating that WUXI BIO (02269) delivered 2025 results exceeding the institution's expectations. Revenue reached RMB 21.79 billion, representing a year-on-year increase of 16.7%. Net profit was RMB 4.91 billion, up 46.3% year-on-year, while adjusted net profit rose 17.9% to RMB 5.64 billion.

Considering improvements in the company's operational efficiency, CICC has raised its forecasts for WUXI BIO's adjusted net profit for 2026 and 2027 by 6.3% and 9.7%, to RMB 6.21 billion and RMB 7.19 billion, respectively. The firm maintained its "Outperform" rating on the stock and increased the target price by 6.7% to HK$48.

The better-than-expected performance and enhanced profitability were primarily attributed to a higher proportion of high-margin business, improved capacity utilization, and greater operational efficiency. The company has guided for 2026 revenue growth of 13-17% year-on-year, factoring in foreign exchange impacts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment